Immuneering flags new press release on atebimetinib preclinical study publication in Cancer Research

Immuneering Corp. Class A

Immuneering Corp. Class A

IMRX

0.00
  • Immuneering disclosed a Cancer Research publication on atebimetinib showing broad, durable preclinical activity across RAS- and RAF-mutant tumor models.
  • Head-to-head in vivo studies showed deeper, more durable tumor growth inhibition than binimetinib, with favorable tolerability in preclinical models.
  • Paper: doi.org/10.1158/0008-5472.CAN-25-4907.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneering Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607211605PRIMZONEFULLFEED9765729) on July 21, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.